デングバキアの世界市場レポート 2025年：疫学、パイプライン分析、市場インサイトと予測

デングバキアの市場規模は今後数年で急成長が見込まれます。2029年には4億470万米ドルに成長し、CAGRは17％に達すると考えられます。予測期間における成長の背景には、デング熱の発生率の上昇、政府資金の増加、官民の協力、デング熱予防に対する一般市民の意識の高まり、ヘルスケアインフラの強化などがあります。予測期間における主要動向としては、ワクチン技術の進歩、継続的な研究開発、ワクチン送達方法の革新、新しい製剤の開発、ワクチンの保管・流通技術の向上などが挙げられます。

デング熱の罹患率の増加がデングバキア市場の成長を牽引すると予想されます。デング熱はイエネコによって媒介されるウイルス感染症で、インフルエンザのような症状や強い痛みを引き起こし、重症化するとデング出血熱やデングショック症候群などの合併症を引き起こし、生命を脅かすこともあります。デング熱の流行の増加は、気候変動、都市化、旅行の増加、蚊の繁殖地の拡大などの要因によるもので、感染率の上昇や予防・治療に対する需要の高まりにつながっています。デングバキアは、ウイルスに対する防御反応を産生するよう免疫系を刺激することでデング熱を予防し、感染や重篤な合併症のリスクを低減し、流行地域における公衆衛生の結果を改善する効果的なワクチンです。例えば、2024年6月、米疾病予防管理センター（CDC）は、2024年の南北アメリカのデング熱患者数が970万人を超え、2023年の460万人から倍増したと報告しました。プエルトリコでは1,498人の患者が発生し公衆衛生上の緊急事態が宣言され、米国人旅行者からは745人の患者が報告されました。その結果、デング熱の高い発生率がデングバキア市場の成長を後押ししています。

海外旅行の増加がデングバキア市場の成長を促進すると予想されます。観光、ビジネス、教育などを含む海外旅行では、デング熱などの感染症が蔓延するリスクが高まります。このリスクの高まりが、ワクチンなどの予防対策への需要を後押ししています。デングバキアは、流行地域におけるデング熱の感染から旅行者を守り、越境疾病伝播のリスクを軽減します。例えば、2024年5月、国家統計局は、英国への海外からの訪問者数が大幅に増加し、2022年の3,120万人から2023年には3,800万人に増加したと報告しました。その結果、海外旅行の増加はデングバキア市場の拡大に貢献すると考えられます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 バイオ医薬品市場における製品特性

• 分子タイプ
• 投与経路（ROA）
• 作用機序（MOA）
• 安全性と有効性

第4章 市場動向と戦略

第5章 市場：金利、インフレ、地政学的要因、新型コロナとその回復が市場に与える影響を含むマクロ経済シナリオ

第6章 世界の成長分析と戦略分析フレームワーク

• 世界のデングバキア：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のデングバキア市場：成長率分析
• 世界のデングバキア市場の実績：規模と成長、2019～2024年
• 世界のデングバキア市場の予測：規模と成長、2024～2029年、2034年
• 世界のデングバキア：総潜在市場規模（TAM）

第7章 世界の価格分析と予測

第8章 市場セグメンテーション

• 世界のデングバキア市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• デングバキア
• その他
• 世界のデングバキア市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• クリニック
• 公衆衛生プログラム
• 世界のデングバキア市場：疾患別、実績と予測、2019～2024年、2024～2029年、2034年
• 過去に感染した人の予防
• 高リスク地域での保護
• 旅行者予防接種
• 小児と青少年の使用

第9章 臨床適応症の世界的疫学

• 薬剤の副作用
• 臨床適応症の発症率と有病率

第10章 地域別・国別分析

• 世界のデングバキア市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のデングバキア市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第11章 アジア太平洋市場

第12章 中国市場

第13章 インド市場

第14章 日本市場

第15章 オーストラリア市場

第16章 韓国市場

第17章 西欧市場

第18章 英国市場

第19章 ドイツ市場

第20章 フランス市場

第21章 東欧市場

第22章 北米市場

第23章 米国市場

第24章 カナダ市場

第25章 南米市場

第26章 中東市場

第27章 アフリカ市場

第28章 競合情勢と企業プロファイル

• デングバキア市場：競合情勢
• デングバキア市場：企業プロファイル
  • Sanofi Pasteur Inc

第29章 世界市場：パイプライン分析

第30章 世界の市場競合ベンチマーキングとダッシュボード

第31章 主要な合併と買収

第32章 最近の市場動向

第33章 市場の潜在力が高い国、戦略

• デングバキア市場、2029年：新たな機会を提供する国
• デングバキア市場、2029年：新たな機会を提供するセグメント
• デングバキア市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第34章 付録

Dengvaxia is a recombinant vaccine designed to protect against dengue fever, a viral disease transmitted by Aedes mosquitoes. It works by stimulating the immune system to generate a targeted response, preventing infection and reducing the risk of severe complications. This vaccine plays a key role in public health efforts in areas where dengue is endemic.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main category of dengvaxia includes the vaccine itself and other related options. Dengvaxia is the first vaccine specifically developed to prevent dengue fever. It aims to provide immunity against the virus that causes the disease, helping to lessen the severity and frequency of dengue outbreaks. As an essential tool in regions prone to dengue, it has been used in various countries to protect at-risk populations. Dengvaxia is distributed through hospitals, clinics, and public health programs, and is administered for multiple purposes, such as preventing the disease in individuals with prior exposure, offering protection in high-risk areas, immunizing travelers, and supporting pediatric and adolescent vaccination.

The dengvaxia market research report is one of a series of new reports from The Business Research Company that provides dengvaxia market statistics, including dengvaxia industry global market size, regional shares, competitors with a dengvaxia market share, detailed dengvaxia market segments, market trends and opportunities, and any further data you may need to thrive in the dengvaxia industry. This dengvaxia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dengvaxia market size is expected to see rapid growth in the next few years. It will grow to $404.7 million in 2029 at a compound annual growth rate (CAGR) of 17%. The growth in the forecast period can be attributed to rising incidence of dengue outbreaks, increased government funding, collaboration between public and private sectors, growing public awareness of dengue prevention, and enhanced healthcare infrastructure. Major trends in the forecast period include advancements in vaccine technology, ongoing research and development, innovations in vaccine delivery methods, development of new formulations, and better vaccine storage and distribution techniques.

The increasing incidence of dengue is expected to drive the growth of the dengvaxia market. Dengue is a viral infection transmitted by Aedes mosquitoes, causing flu-like symptoms, intense pain, and, in severe cases, complications such as dengue hemorrhagic fever or dengue shock syndrome, which can be life-threatening. The rising prevalence of dengue is attributed to factors such as climate change, urbanization, increased travel, and the expansion of mosquito breeding grounds, leading to higher infection rates and an increased demand for prevention and treatment. Dengvaxia is an effective vaccine that prevents dengue by stimulating the immune system to produce protective responses against the virus, reducing the risk of infection and severe complications, and improving public health outcomes in endemic areas. For example, in June 2024, the Centers for Disease Control and Prevention (CDC) reported that the Americas had over 9.7 million dengue cases in 2024, double the 4.6 million cases in 2023. Puerto Rico declared a public health emergency with 1,498 cases, and 745 cases were reported among U.S. travelers. As a result, the high incidence of dengue is propelling the growth of the dengvaxia market.

The rise in international travel is expected to fuel the growth of the dengvaxia market. International travel, which includes tourism, business, and education, increases the risk of spreading infectious diseases such as dengue. This heightened risk drives the demand for preventive measures such as vaccines. Dengvaxia helps protect travelers from contracting dengue in endemic areas and reduces the risk of disease transmission across borders. For instance, in May 2024, the Office for National Statistics reported a significant increase in the number of international visits to the UK, rising from 31.2 million in 2022 to 38.0 million in 2023. As a result, the growth in international travel will contribute to the expansion of the dengvaxia market.

The rising healthcare expenditures are expected to further accelerate the growth of the dengvaxia market. Healthcare expenditures refer to the financial resources allocated by governments, private entities, or individuals for healthcare services, medical treatments, and health-related activities. The growth in healthcare expenditures is driven by factors such as the increasing demand for medical services, advancements in healthcare technology, and the rising prevalence of chronic diseases, leading to greater investment in healthcare infrastructure and treatments. The expenditure on Dengvaxia focuses on prevention, aiming to reduce the long-term costs of treating dengue and managing outbreaks. For example, in May 2024, the Office for National Statistics reported a 5.6% increase in nominal healthcare expenditure from 2022 to 2023, marking a significant acceleration compared to the 0.9% growth in 2022. Therefore, rising healthcare expenditures will further stimulate the growth of the dengvaxia market.

The key company operating in the dengvaxia market is Sanofi Pasteur Inc.

Asia-Pacific was the largest region in the dengvaxia market in 2024. Latin America is expected to be the fastest-growing region in the forecast period. The regions covered in dengvaxia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the dengvaxia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dengvaxia market consists of sales of dengvaxia (CYD-TDV), disposable syringes and needles, pre-filled syringes of dengvaxia, and unit-dose packaging. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Dengvaxia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on dengvaxia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for dengvaxia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dengvaxia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Dengvaxia; Other Types
• 2) By Distribution Channel: Hospitals; Clinics; Public Health Programs
• 3) By Clinical Indication: Prevention In Previously Infected Individuals; Protection In High-Risk Regions; Traveler Immunization; Pediatric And Adolescent Use
• Companies Mentioned: Sanofi Pasteur Inc.
• Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Dengvaxia Market Characteristics

3. Dengvaxia Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Dengvaxia Market Trends And Strategies

5. Dengvaxia Market -Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Dengvaxia Growth Analysis And Strategic Analysis Framework

• 6.1. Global Dengvaxia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Dengvaxia Market Growth Rate Analysis
• 6.4. Global Dengvaxia Historic Market Size and Growth, 2019 - 2024, Value ($ Million)
• 6.5. Global Dengvaxia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Million)
• 6.6. Global Dengvaxia Total Addressable Market (TAM)

7. Global Dengvaxia Pricing Analysis & Forecasts

8. Dengvaxia Market Segmentation

• 8.1. Global Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• Dengvaxia
• Other Types
• 8.2. Global Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• Hospitals
• Clinics
• Public Health Programs
• 8.3. Global Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• Prevention In Previously Infected Individuals
• Protection In High-Risk Regions
• Traveler Immunization
• Pediatric And Adolescent Use

9. Global Dengvaxia Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Dengvaxia Market Regional And Country Analysis

• 10.1. Global Dengvaxia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 10.2. Global Dengvaxia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

11. Asia-Pacific Dengvaxia Market

• 11.1. Asia-Pacific Dengvaxia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 11.3. Asia-Pacific Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 11.4. Asia-Pacific Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

12. China Dengvaxia Market

• 12.1. China Dengvaxia Market Overview
• 12.2. China Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
• 12.3. China Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
• 12.4. China Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million

13. India Dengvaxia Market

• 13.1. India Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 13.2. India Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 13.3. India Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

14. Japan Dengvaxia Market

• 14.1. Japan Dengvaxia Market Overview
• 14.2. Japan Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 14.3. Japan Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 14.4. Japan Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

15. Australia Dengvaxia Market

• 15.1. Australia Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 15.2. Australia Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 15.3. Australia Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

16. South Korea Dengvaxia Market

• 16.1. South Korea Dengvaxia Market Overview
• 16.2. South Korea Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 16.3. South Korea Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 16.4. South Korea Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

17. Western Europe Dengvaxia Market

• 17.1. Western Europe Dengvaxia Market Overview
• 17.2. Western Europe Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 17.3. Western Europe Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 17.4. Western Europe Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

18. UK Dengvaxia Market

• 18.1. UK Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 18.2. UK Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 18.3. UK Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

19. Germany Dengvaxia Market

• 19.1. Germany Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 19.2. Germany Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 19.3. Germany Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

20. France Dengvaxia Market

• 20.1. France Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 20.2. France Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 20.3. France Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

21. Eastern Europe Dengvaxia Market

• 21.1. Eastern Europe Dengvaxia Market Overview
• 21.2. Eastern Europe Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 21.3. Eastern Europe Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 21.4. Eastern Europe Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

22. North America Dengvaxia Market

• 22.1. North America Dengvaxia Market Overview
• 22.2. North America Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 22.3. North America Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 22.4. North America Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

23. USA Dengvaxia Market

• 23.1. USA Dengvaxia Market Overview
• 23.2. USA Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 23.3. USA Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 23.4. USA Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

24. Canada Dengvaxia Market

• 24.1. Canada Dengvaxia Market Overview
• 24.2. Canada Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 24.3. Canada Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 24.4. Canada Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

25. South America Dengvaxia Market

• 25.1. South America Dengvaxia Market Overview
• 25.2. South America Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 25.3. South America Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 25.4. South America Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

26. Middle East Dengvaxia Market

• 26.1. Middle East Dengvaxia Market Overview
• 26.2. Middle East Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 26.3. Middle East Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 26.4. Middle East Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

27. Africa Dengvaxia Market

• 27.1. Africa Dengvaxia Market Overview
• 27.2. Africa Dengvaxia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 27.3. Africa Dengvaxia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 27.4. Africa Dengvaxia Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

28. Dengvaxia Market Competitive Landscape And Company Profiles

• 28.1. Dengvaxia Market Competitive Landscape
• 28.2. Dengvaxia Market Company Profiles
  • 28.2.1. Sanofi Pasteur Inc Overview, Products and Services, Strategy and Financial Analysis

29. Global Dengvaxia Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Dengvaxia Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Dengvaxia Market

32. Recent Developments In The Dengvaxia Market

33. Dengvaxia Market High Potential Countries, Segments and Strategies

• 33.1 Dengvaxia Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Dengvaxia Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Dengvaxia Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer